明報新聞網

復宏漢霖生物注射液獲歐洲委員會批兩項新增適應症

10 5 月, 2026

One Min Read

2 Views

復宏漢霖生物（2696）發通告指，歐盟委員會已批准，公司自主開發的斯魯利單抗注射液（商品名：漢斯狀®）兩項新增適應症。

原文: https://finance.mingpao.com/fin/instantf/20260510/1778408882226/%E5%BE%A9%E5%AE%8F%E6%BC%A2%E9%9C%96%E7%94%9F%E7%89%A9%E6%B3%A8%E5%B0%84%E6%B6%B2%E7%8D%B2%E6%AD%90%E6%B4%B2%E5%A7%94%E5%93%A1%E6%9C%83%E6%89%B9%E5%85%A9%E9%A0%85%E6%96%B0%E5%A2%9E%E9%81%A9%E6%87%89%E7%97%87%22%20target=%22blank

Last Update: 10 5 月, 2026

Written By

Other Articles

Previous

路透：阿里巴巴擬整合AI平台千問與淘寶推對話式購物

Next

‘The gains will be substantial’: The AI shock is looking a lot like the China shock, and a top economist says that’s actually good news

Related Posts

明報新聞網

天氣｜天文台：大致多雲　日間部分時間有陽光

1 Min Read

明報新聞網

短片：西班牙葡萄牙恢復供電　停電期間火車、飛機停運

1 Min Read

明報新聞網

抽象派畫家Mark Rothko 4.4億元作品荷蘭展出　遭小孩刮花

1 Min Read

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept